164 related articles for article (PubMed ID: 14632470)
41. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
42. LQTA-QSAR: a new 4D-QSAR methodology.
Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
[TBL] [Abstract][Full Text] [Related]
43. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
44. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
45. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 protease cleavage site prediction based on amino acid property.
Niu B; Lu L; Liu L; Gu TH; Feng KY; Lu WC; Cai YD
J Comput Chem; 2009 Jan; 30(1):33-9. PubMed ID: 18496789
[TBL] [Abstract][Full Text] [Related]
47. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
48. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
[TBL] [Abstract][Full Text] [Related]
49. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
Xiao Z; Varma S; Xiao YD; Tropsha A
J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
[TBL] [Abstract][Full Text] [Related]
50. The signature molecular descriptor. 1. Using extended valence sequences in QSAR and QSPR studies.
Faulon JL; Visco DP; Pophale RS
J Chem Inf Comput Sci; 2003; 43(3):707-20. PubMed ID: 12767129
[TBL] [Abstract][Full Text] [Related]
51. A priori molecular descriptors in QSAR: a case of HIV-1 protease inhibitors. II. Molecular graphics and modeling.
Kiralj R; Ferreira MM
J Mol Graph Model; 2003 Jun; 21(6):499-515. PubMed ID: 12676237
[TBL] [Abstract][Full Text] [Related]
52. Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection.
Tetko IV; Sushko I; Pandey AK; Zhu H; Tropsha A; Papa E; Oberg T; Todeschini R; Fourches D; Varnek A
J Chem Inf Model; 2008 Sep; 48(9):1733-46. PubMed ID: 18729318
[TBL] [Abstract][Full Text] [Related]
53. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.
Kuo CL; Assefa H; Kamath S; Brzozowski Z; Slawinski J; Saczewski F; Buolamwini JK; Neamati N
J Med Chem; 2004 Jan; 47(2):385-99. PubMed ID: 14711310
[TBL] [Abstract][Full Text] [Related]
54. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
[TBL] [Abstract][Full Text] [Related]
55. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
[TBL] [Abstract][Full Text] [Related]
56. Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.
Katritzky AR; Oliferenko A; Lomaka A; Karelson M
Bioorg Med Chem Lett; 2002 Dec; 12(23):3453-7. PubMed ID: 12419382
[TBL] [Abstract][Full Text] [Related]
57. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
Shen M; Béguin C; Golbraikh A; Stables JP; Kohn H; Tropsha A
J Med Chem; 2004 Apr; 47(9):2356-64. PubMed ID: 15084134
[TBL] [Abstract][Full Text] [Related]
58. Topological models for the prediction of HIV-protease inhibitory activity of tetrahydropyrimidin-2-ones.
Lather V; Madan AK
J Mol Graph Model; 2005 Jan; 23(4):339-45. PubMed ID: 15670954
[TBL] [Abstract][Full Text] [Related]
59. Prediction of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas based on the heuristic method, support vector machine and projection pursuit regression.
Yuan Y; Zhang R; Hu R; Ruan X
Eur J Med Chem; 2009 Jan; 44(1):25-34. PubMed ID: 18433938
[TBL] [Abstract][Full Text] [Related]
60. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
